Author
Listed:
- Mrudula Thombre
- Suyash Thorat
- Saurabh Thopate
- Nitin Neharkar
- Vijaya Barge
Abstract
The usage of fixed dose combination (FDC) tablets of Lamivudine, Dolutegravir and Tenofovir Disoproxil Fumarate (TDF) is increasing due to increased incidences of HIV/Hepatitis B and HIV/TB co-infections. This is likely to increase the financial crisis due to limited resources for funding procurement of ready-made products from the pharmaceuticals manufacturing leading countries. Therefore, production of local oral tablets containing Lamivudine and TDF FDC is inevitable. Lamivudine 300 mg/TDF 300 mg tablets were developed and optimized by D-optimal mixture design and produced by direct compression technique. The first-ever 2-drug regimen approved for the treatment of HIV-1 infection for treatment-naive people living with HIV (PLWH), consisting of the integrase inhibitor dolutegravir (DTG) and the nucleoside reverse transcriptase inhibitor (NRTI) lamivudine (3TC), is reviewed in this paper. The chemical composition and properties, pharmacokinetic and pharmacodynamics profile, and clinical trial data on efficacy and safety of DTG/3TC are presented. An expert opinion aims to highlight important considerations for the use of DTG/3TC in the context of existing and emerging ARV options.
Suggested Citation
Mrudula Thombre & Suyash Thorat & Saurabh Thopate & Nitin Neharkar & Vijaya Barge, 2024.
"A Review on Antiretroviral Tablets,"
International Journal of Scientific Research in Science and Technology, Technoscience Academy, vol. 11(2), pages 380-386, April.
Handle:
RePEc:etm:ijsrst:v11:y2024:i2:id:49
DOI: 10.32628/IJSRST52411252
Download full text from publisher
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:etm:ijsrst:v11:y2024:i2:id:49. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Pankaj Sharma (email available below). General contact details of provider: https://ijsrst.com/home .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.